Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis
Simons G, Bywall KS, Englbrecht M, Johansson EC, Disantostefano RL, Radawski C, Veldwijk J, Raza K, Falahee M (2022)
Publication Type: Journal article
Publication year: 2022
Journal
DOI: 10.1080/03009742.2022.2116805
Abstract
Objective Some immunomodulatory drugs have been shown to delay the onset of, or lower the risk of developing, rheumatoid arthritis (RA), if given to individuals at risk. Several trials are ongoing in this area; however, little evidence is currently available about the views of those at risk of RA regarding preventive treatment. Method Three focus groups and three interviews explored factors that are relevant to first degree relatives (FDRs) of RA patients and members of the general public when considering taking preventive treatment for RA. The semi-structured qualitative interview prompts explored participant responses to hypothetical attributes of preventive RA medicines. Transcripts of focus group/interview proceedings were inductively coded and analysed using a framework approach. Results Twenty-one individuals (five FDRs, 16 members of the general public) took part in the study. Ten broad themes were identified describing factors that participants felt would influence their decisions about whether to take preventive treatment if they were at increased risk of RA. These related either directly to features of the specific treatment or to other factors, including personal characteristics, attitude towards taking medication, and an individual's actual risk of developing RA. Conclusion This research highlights the importance of non-treatment factors in the decision-making process around preventive treatments, and will inform recruitment to clinical trials as well as information to support shared decision making by those considering preventive treatment. Studies of treatment preferences in individuals with a confirmed high risk of RA would further inform clinical trial design.
Authors with CRIS profile
Involved external institutions
Janssen Global Services, LLC
United States (USA) (US)
Erasmus University Rotterdam (EUR) / Erasmus Universiteit Rotterdam
Netherlands (NL)
Swedish Rheumatism Association
Sweden (SE)
University of Birmingham
United Kingdom (GB)
Uppsala University
Sweden (SE)
Eli Lilly and Company
United States (USA) (US)
United States (USA) (US)
Erasmus University Rotterdam (EUR) / Erasmus Universiteit Rotterdam
Netherlands (NL)
Swedish Rheumatism Association
Sweden (SE)
University of Birmingham
United Kingdom (GB)
Uppsala University
Sweden (SE)
Eli Lilly and Company
United States (USA) (US)
How to cite
APA:
Simons, G., Bywall, K.S., Englbrecht, M., Johansson, E.C., Disantostefano, R.L., Radawski, C.,... Falahee, M. (2022). Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis. Scandinavian Journal of Rheumatology. https://doi.org/10.1080/03009742.2022.2116805
MLA:
Simons, Gwenda, et al. "Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis." Scandinavian Journal of Rheumatology (2022).
BibTeX: Download